| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Circulating tumor cells in patients with breast cancer dormancy.
|
Clin Cancer Res
|
2004
|
4.48
|
|
2
|
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset.
|
Blood
|
2013
|
1.93
|
|
3
|
Thrombosis and a hypercoagulable state in HIV-infected patients.
|
Clin Appl Thromb Hemost
|
2004
|
1.84
|
|
4
|
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
|
Neurology
|
2011
|
1.80
|
|
5
|
Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit.
|
Clin Cancer Res
|
2004
|
1.79
|
|
6
|
Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.
|
Clin Cancer Res
|
2002
|
1.74
|
|
7
|
Microchip-based immunomagnetic detection of circulating tumor cells.
|
Lab Chip
|
2011
|
1.59
|
|
8
|
Comparison of a rapid platelet function assay--Verify Now Aspirin--with whole blood impedance aggregometry for the detection of aspirin resistance.
|
Thromb Res
|
2007
|
1.52
|
|
9
|
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
|
Int J Cancer
|
2003
|
1.43
|
|
10
|
Retracted
Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer.
|
Cancer Lett
|
2006
|
1.40
|
|
11
|
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
|
Hematol Oncol Clin North Am
|
2005
|
1.07
|
|
12
|
Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
|
Mod Pathol
|
2002
|
1.05
|
|
13
|
IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation.
|
J Biol Chem
|
2005
|
1.04
|
|
14
|
Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes.
|
Cancer Res
|
2004
|
1.02
|
|
15
|
Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
|
Clin Cancer Res
|
2003
|
1.00
|
|
16
|
Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features.
|
Clin Cancer Res
|
2003
|
0.99
|
|
17
|
Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods.
|
Clin Appl Thromb Hemost
|
2005
|
0.98
|
|
18
|
Versatile immunomagnetic nanocarrier platform for capturing cancer cells.
|
ACS Nano
|
2013
|
0.96
|
|
19
|
PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
|
Cancer Res
|
2004
|
0.95
|
|
20
|
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
|
J Thorac Oncol
|
2009
|
0.92
|
|
21
|
Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.
|
Transl Res
|
2011
|
0.90
|
|
22
|
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.
|
Neurology
|
2013
|
0.89
|
|
23
|
Acquired platelet dysfunction.
|
Hematol Oncol Clin North Am
|
2007
|
0.88
|
|
24
|
Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates.
|
Clin Cancer Res
|
2004
|
0.85
|
|
25
|
Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
|
Platelets
|
2007
|
0.83
|
|
26
|
Targeting methionine auxotrophy in cancer: discovery & exploration.
|
Expert Opin Biol Ther
|
2011
|
0.82
|
|
27
|
Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents.
|
J Urol
|
2002
|
0.82
|
|
28
|
In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.
|
Cancer Res
|
2003
|
0.82
|
|
29
|
Upregulation of TRAG3 gene in urothelial carcinoma of the bladder.
|
Int J Cancer
|
2010
|
0.81
|
|
30
|
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
|
Am J Clin Oncol
|
2008
|
0.79
|
|
31
|
Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.
|
Acta Pharmacol Sin
|
2006
|
0.79
|
|
32
|
MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast.
|
Appl Immunohistochem Mol Morphol
|
2004
|
0.79
|
|
33
|
Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy.
|
Br J Haematol
|
2006
|
0.78
|
|
34
|
Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.
|
Cancer Sci
|
2014
|
0.78
|
|
35
|
Hyperhomocysteinemia and thrombosis.
|
Hematol Oncol Clin North Am
|
2003
|
0.77
|
|
36
|
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy.
|
Hematol Oncol Clin North Am
|
2003
|
0.76
|
|
37
|
Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.
|
Cancer Res
|
2004
|
0.76
|
|
38
|
Cobalamin profiles in patients after urinary diversion.
|
J Urol
|
2002
|
0.76
|
|
39
|
In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts.
|
Melanoma Res
|
2014
|
0.76
|
|
40
|
Incidence of isolated heparin-induced thrombocytopenia and risk of thrombosis by IgG-specific anti-PF4/heparin ELISA.
|
Clin Appl Thromb Hemost
|
2011
|
0.75
|